Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP441 MAD study in healthy adults
NCT05720494Phase 1Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in narcolepsy and idiopathic hypersomnia (IH) comparing JZP441 with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-emergent Adverse Events, Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Levels of JZP441 and 8 more. Started Jan 2023; status: completed.
02
Drugs
JZP441
03
Conditions
narcolepsyidiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT05720494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720494.